natgillin/translations-raw huggingface dataset:
The human immunodeficiency virus (HIV-1) encodes an aspartyl protease that is essential for the cleavage and maturation of viral protein precursors.
Humani virus imunodeficijencije (HIV-1) kodira aspartilproteazu koja je nužna za segmentaciju i sazrijevanje prekursora virusnih proteina.
The human normal immunoglobulin 10% should be clear and colourless or pale yellow.
Normalni ljudski imunoglobulin 10% mora biti bistar i bezbojan ili blijedožut.
The Human Papillomavirus (HPV) types contained in the vaccine (HPV types 16 and 18) are responsible for approximately 70% of cervical cancers , 90% of anal cancers, 70% of HPV-related pre-cancerous lesions of the vulva and vagina and 78% of HPV-related pre-cancerous lesions of the anus.
Tipovi humanog papilomavirusa (HPV) koji su sadržani u cjepivu (HPV tipovi 16 i 18) odgovorni su za oko 70% slučajeva raka cerviksa, 90% slučajeva raka anusa, 70% s HPV-om povezanih prekanceroznih lezija stidnice i rodnice i 78% prekanceroznih analnih lezija povezanih s HPV-om.
The human protein binding of both ceftazidime and avibactam is approximately 10% and 8%, respectively.
Vezanje i ceftazidima i avibaktama za proteine kod ljudi iznosi otprilike 10% odnosno 8%.
The human radiation dose estimates derived from biodistribution studies in mice with [90Y]- or
Prema procjenama doza zračenja za ljude izvedenim iz ispitivanja biološke raspodjele
The human relevance of these findings is currently unknown.
Značaj ovog nalaza za ljude trenutno nije poznat.
The Humira pre-filled pen is a single-use grey- and plum-coloured pen which contains a glass syringe with Humira.
Napunjena brizgalica lijeka Humira je sivo i ljubičasto obojena brizgalica za jednokratnu uporabu koja sadrži staklenu štrcaljku s otopinom lijeka Humira.
The Humira pre-filled pen is available in packs containing 1, 2, 4, and 6 pre-filled pens.
Napunjena brizgalica lijeka Humira je dostupna u pakiranjima od 1, 2, 4 ili 6 napunjenih brizgalica.
The Humira pre-filled syringe is a glass syringe containing a solution of adalimumab.Each pack contains 1, 2, 4 or 6 pre-filled syringes for patient use with 1, 2, 4 or 6 alcohol pads, respectively.
Jedno pakiranje sadrži 1, 2, 4 ili 6 napunjenih štrcaljki za uporabu od strane bolesnika s 1, 2, 4, odnosno 6 jastučića natopljenih alkoholom.
The Humira pre-filled syringe is a glass syringe with needleguard containing a solution of adalimumab.
Napunjena štrcaljka lijeka Humira je staklena štrcaljka sa štitnikom za iglu koja sadrži otopinu adalimumaba.
The Humira syringe should NEVER be reused.
Uporabljena štrcaljka lijeka Humira se NIKADA ne smije ponovno uporabiti.
The hydration status of patients must be assessed prior to and following administration of Zoledronic acid medac to assure that they are adequately hydrated.
Prije i poslije primjene Zoledronatne kiseline medac mora se provjeriti status hidracije bolesnika kako bi se osiguralo da su primjereno hidrirani.
The hydration status of patients must be assessed prior to and following administration of Zoledronic acid Teva to assure that they are adequately hydrated.
Prije i poslije primjene Zoledronatne kiseline Teva mora se provjeriti status hidracije bolesnika kako bi se osiguralo da su primjereno hidrirani.
The hydration status of patients must be assessed prior to and following administration of Zometa to ensure that they are adequately hydrated.
Prije i poslije primjene Zomete mora se provjeriti status hidracije bolesnika kako bi se osiguralo da su primjereno hidrirani.
The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta- blockers.
Hipertenzijska reakcija izazvana naglim prestankom uzimanja klonidina može se pojačati pri uzimanju beta-blokatora.
The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers.
Kod uzimanja beta blokatora može se pojačati hipertenzivna reakcija kod naglog prestanka uzimanja klonidina.
The hypotensive effects of dexmedetomidine may be of greater significance in those patients with pre- existing hypotension (especially if not responsive to vasopressors), hypovolaemia, chronic hypotension or reduced functional reserve such as patients with severe ventricular dysfunction and the elderly and special care is warranted in these cases (see section 4.3).
Učinak deksmedetomidina na smanjivanje krvnoga tlaka može biti od veće važnosti kod bolesnika s već razvijenom hipotenzijom (osobito ako ona ne reagira na vazopresore), hipovolemijom, kroničnom hipotenzijom ili smanjenom funkcionalnom rezervom poput bolesnika s teškim oblikom ventrikularne disfunkcije te starijih osoba pa je u takvim slučajevima potreban poseban oprez (vidjeti dio 4.3).
The I-Neb AAD nebuliser has been shown to be suitable for the administration of Ventavis 10 microgram/ml (1 ml ampoule with white and yellow rings).
Atomizator I-Neb AAD pokazao se prikladnim za primjenu lijeka Ventavis 10 mikrograma/ml (ampula od 1 ml s bijelim i žutim prstenom).
The I-Neb AAD nebuliser has been shown to be suitable for the administration of Ventavis 10 microgram/ml (1 ml ampoule) and 20 microgram/ml nebuliser solution.
Atomizator I-Neb AAD pokazao se prikladnim za primjenu Ventavis 10 mikrograma/ml (ampula od 1 ml) i 20 mikrograma/ml otopine za atomizator.
The I-Neb AAD System is a portable, hand-held, vibrating mesh technology nebuliser system.
Sustav I-Neb AAD je prijenosni ručni atomizatorski sustav s tehnologijom vibrirajuće mrežice.
The IB D388/QX vaccine should only be applied in hatcheries if adequate controls are in place to avoid the spread of the vaccine virus to birds that will be transported to non-IB QX exposed flocks.
IB D388 vakcina treba se primjenjivati u valionicama kod pilića starih 1 dan ili starijih ako se primjenjuje odgovarajuća kontrola kako bi se izbjeglo širenje vakcinalnog virusa na ptice koje će se premjestiti u jata koja nisu izložena QX soju virusa zaraznog bronhitisa.
The Ibandronic Acid Teva film-coated tablets are white, biconvex, capsule-shaped, engraved “50” on one side and plain on the other.
Ibandronatna kiselina Teva filmom obložene tablete su bijele, bikonveksne tablete oblika kapsule s utisnutom oznakom „50“ na jednoj strani i bez oznake na drugoj strani.
The Ibandronic Acid Teva film-coated tablets are white, biconvex, capsule-shaped, engraved “I150” on one side and plain on the other.
Ibandronatna kiselina Teva filmom obložene tablete su bijele, bikonveksne tablete u obliku kapsula s utisnutom oznakom „1150“ na jednoj strani i bez oznake na drugoj strani.
The ibuprofen dose is adjusted to the body weight as follows:
Dozu ibuprofena treba prilagoditi prema tjelesnoj težini djeteta kako slijedi:
The IC50 for dolutegravir in various lab-strains using PBMC was 0.5 nM, and when using MT-4 cells it ranged from 0.7-2 nM.
IC50 za dolutegravir u različitim laboratorijskim sojevima na mononuklearnim stanicama periferne krvi iznosio je 0,5 nM, a na MT-4 stanicama kretao se u rasponu od 0,7-2 nM.
The IC50 for dolutegravir in various labstrains using PBMC was 0.5 nM, and when using MT-4 cells it ranged from 0.7-2 nM.
IC50 za dolutegravir u različitim laboratorijskim sojevima na mononuklearnim stanicama periferne krvi iznosio je 0,5 nM, a na MT-4 stanicama kretao se u rasponu od 0,7-2 nM.
The IC50 for wild-type HXB2 is 0.24 to 0.6 M, while the IC50 for M184V containing HXB2 is >100 to 500 M.
IC50 za divlji soj HXB2 bila je 0,24 do 0,6 µM, dok je IC50 za M184V koja sadrži HXB2 bila >100 do 500 µM.
The IC50 values of abacavir against HIV-1 Group M subtypes (A-G) ranged from 0.002 to 1.179 M, against Group O from 0.022 to 1.21 M, and against HIV-2 isolates, from 0.024 to 0.49 M.
Vrijednosti IC50 abakavira za HIV-1 skupine M podvrsta (A-G), kretale su se u rasponu od
The identification and maintenance of a list of all Uptravi prescribers;
Sastavljanje i održavanje popisa svih propisivača Uptravija;
The identified metabolites do not show anti-mycobacterial activity but some contribute to QTc prolongation, mainly DM- 6705.
Identificirani metaboliti ne pokazuju antimikobakterijsku aktivnost ali neki doprinose produljenju QTc, uglavnom metabolit DM- 6705.
The identified or potential risk of immunogenicity that might lead to immune-mediated symptoms.
Identificirani ili potencijalni rizik od imunogenosti koji bi mogao dovesti do simptoma od strane imunološkog sustava.
The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate)
Prepoznat rizik od sinergije između hepatotoksičnosti ili hematotoksičnosti i kombinirane terapije s nekim drugim antireumatikom koji modificira tijek bolesti (primjerice metotreksatom).
The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate).
Prepoznat rizik od sinergije između hepatotoksičnosti ili hematotoksičnosti i kombinirane terapije s nekim drugim antireumatikom koji modificira tijek bolesti (primjerice metotreksatom).
The IM injection should be given slowly and deeply into the muscle.
Otopina Ringerovog laktata za injekciju.
The images should be viewed in a systematic manner (Figure 1) starting at the level of pons (p) and scrolling up through
Snimke je potrebno pregledavati sistematično (Slika 1) počevši od razine mosta (p) prema gore kroz
The imaging dose of [111In]-radiolabelled Zevalin was always given immediately following an infusion with rituximab at 250 mg/m² to deplete peripheral CD20+ cells and to optimise bio- distribution.
Doza Zevalina radioaktivno označenog izotopom [111In] za snimanje uvijek se davala neposredno nakon infuzije rituksimabom u dozi od 250 mg/m² radi smanjenja broja perifernih CD20+ stanica i optimizacije biološke raspodjele.
The imaging procedure should be completed within 1 hour of administration of the contrast medium.
Dijagnostičko prikazivanje treba završiti unutar sat vremena od injiciranja kontrastnog sredstva.
The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with zoledronic acid 4 mg every 3 – 4 weeks in oncology patients.
Opažena neravnoteža u ovom ispitivanju nije bila primijećena u drugim ispitivanjima zoledronatne kiseline, uključujući ispitivanja zoledronatne kiseline u dozi od 4 mg primijenjene svaka 3 do 4 tjedna u onkoloških bolesnika.
The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with zoledronic acid 4 mg every 3-4 weeks in oncology patients.
Opažena neravnoteža u ovom ispitivanju nije bila opažena u drugim ispitivanjima zoledronatne kiseline, uključujući ispitivanja zoledronatne kiseline u dozi od 4 mg primijenjene svaka 3 do 4 tjedna u onkoloških bolesnika.
The IMBRUVICA dose should be lowered to 140 mg once daily (one capsule) when used concomitantly with moderate CYP3A4 inhibitors.
Doza lijeka IMBRUVICA mora se smanjiti na 140 mg jedanput na dan (jedna kapsula) kada se uzima istovremeno s umjerenim CYP3A4 inhibitorima.
The IMBRUVICA dose should be reduced to 140 mg once daily (one capsule) or withheld for up to 7 days when it is used concomitantly with strong CYP3A4 inhibitors.
Doza lijeka IMBRUVICA mora se smanjiti na 140 mg jedanput na dan (jedna kapsula) ili prekinuti primjena na najviše 7 dana, kada se uzima istodobno sa snažnim CYP3A4 inhibitorima.
The immediate-release part provides a rapid onset of absorption and the extended release part provides a more extended plasma profile of cortisol.
Dio koji trenutno oslobađa lijek omogućava brzi početak apsorpcije, dok dio s odgođenim oslobađanjem produljuje profil kortizola u plazmi.
The immune response observed in the children 2-10 years of age was very similar to those observed in the V59P8 study shown above: immune response to Menveo at 1 month post vaccination, as measured by percentage of subjects with seroresponse, hSBA≥1:8 and GMTs, was non-inferior to ACWY-PS.
Imunološki odgovor uočen u djece u dobi od 2 do 10 godina bio je vrlo sličan onome u ispitivanju V59P8 prikazanom u tekstu iznad: imunološki odgovor na Menveo mjesec dana nakon cijepljenja, mjeren postotkom ispitanika sa serološkim odgovorima hSBA≥1:8 i GMTs, bio je neinferioran prema ACWY-PS.
The immune response to Fluarix was satisfactory.
Imunološki odgovor na Fluarix bio je zadovoljavajući.
The immune responses after the booster dose in this age group were generally similar to those observed after the booster dose in infants who had been primed with 3 doses below 6 months of age.
Imunološki odgovor nakon doze docjepljivanja u ovoj dobnoj skupini bio je općenito sličan onom primijećenom nakon dodatne doze u dojenčadi mlađe od 6 mjeseci koja su primila 3 primarne doze cjepiva.
The immune responses to all four QIV strains were noninferior when Prevenar 13 was given concomitantly with QIV compared to when QIV was given alone.
Imunološki odgovori na sva 4 soja iz četverovalentnog inaktiviranog cjepiva bili su neinferiorni kada se Prevenar 13 davao istovremeno sa četverovalentnim inaktiviranim cjepivom, u usporedbi s onima kada se četverovalentno inaktivirano cjepivo davalo samo.
The immune responses to Prevenar 13 were noninferior when Prevenar 13 was given concomitantly with QIV compared to when Prevenar 13 was given alone.
Imunološki odgovori na Prevenar 13 bili su neinferiorni kada se Prevenar 13 davao istovremeno sa četverovalentnim inaktiviranim cjepivom u usporedbi s onima kada se Prevenar 13 davao sam.
The immune responses to PRP, PT and FHA antigens one month after 2 doses given at 2 and 4 months of age were similar to those observed one month after a 2-dose priming given at 3 and 5 months of age: anti-PRP titers ≥ 0.15 µg/ml were observed in 73.0% of individuals, anti-PT vaccine response in 97.9% of individuals and anti-FHA vaccine response in 98.6% of individuals.
Imunološki odgovor na PRP, PT i FHA antigene mjesec dana nakon davanja 2 doze u dobi od 2 i 4 mjeseca starosti bio je sličan onome koji je zapažen mjesec dana nakon primarnog cijepljenja s 2 doze u dobi od 3 i 5 mjeseci: titar anti-PRP protutijela ≥ 0,15µg/ml zapažen je u 73,0% ispitanika, anti-PT serološki odgovor u 97,9% ispitanika, a anti-FHA serološki odgovor u 98,6% ispitanika.
The immune system will then be able to produce antibodies more quickly and in large numbers when it comes into contact with the virus again.
Imunosni sustav potom će moći brže i u većim količinama proizvoditi antitijela kada ponovno bude izložen virusu.
The immune system will then be able to produce antibodies more quickly when it is exposed to the bacterium again.
Imunosni sustav može zatim brže stvarati protutijela pri ponovnom izlaganju bakteriji.
The immune system will then be able to produce antibodies more quickly when it is exposed to the virus again.
Imunološki sustav potom će moći proizvoditi protutijela brže kad je ponovno izloženo virusu.
The immunisation schedules for Synflorix should be based on official recommendations.
Raspored imunizacije cjepivom Synflorix mora se zasnivati na službenim preporukama.
The immunogenicity after two doses administered two months apart in children 6 months to 26 months of age has been documented in three studies whose results are summarised in Table 4.
Imunogenost nakon dvije doze primijenjene u razmaku od dva mjeseca u djece u dobi od 6 mjeseci do 26 mjeseci dokumentirana je u tri ispitivanja čiji su rezultati sažeti u Tablici 4.
The immunogenicity and safety of subsequent formulations of the vaccine have also been examined in studies.
Imunogenost i sigurnost naknadnih formulacija cjepiva također su proučavane u ispitivanjima.
The immunogenicity evaluation was performed in a subset of the study population and included the determination of the seroconversion rate (SCR), defined as JEV neutralizing antibody titer ≥1:10, the proportion of subjects achieving an at least four- fold increase in antibody titers and the geometric mean titer (GMT) at Day 56 and Month 7, by dose and by age group.
Procjena imunogenosti provedena je na podskupini populacije u ispitivanju i uključivala je određivanje stope serokonverzije (SCR), definirane kao titar neutralizirajućih protutijela na virus JE ≥1:10, udio ispitanika koji su postigli najmanje četverostruki porast titra protutijela i geometrijsku sredinu titra (GMT) na 56. dan i 7. mjesec, po dozi i po dobnoj skupini.
The immunogenicity of a booster dose at 18 to 24 months of age was evaluated in approximately 200 preterm infants.
Imunogenost doze docjepljivanja primijenjene između 18. i 24. mjeseca života ocjenjivala se u približno 200 nedonoščadi.
The immunogenicity of ADVATE was evaluated in previously treated patients.
Imunogenost lijeka ADVATE ispitivala se u prethodno liječenih bolesnika.
The immunogenicity of Hexacima in children over 24 months of age has not been studied in clinical trials.
Imunogenost cjepiva Hexacima u djece starije od 24 mjeseca nije ispitivana u kliničkim ispitivanjima.
The immunogenicity of Hexyon in children over 24 months of age has not been studied in clinical trials.
Imunogenost cjepiva Hexyon u djece starije od 24 mjeseca nije ispitivana u kliničkim ispitivanjima.
The immunogenicity of Iblias was evaluated in previously treated patients.
Imunogenost lijeka Iblias procijenjena je u prethodno liječenih bolesnika.
The immunogenicity of Infanrix hexa was evaluated across three studies including approximately 300 preterm infants (born after a gestation period of 24 to 36 weeks) following a 3-dose primary vaccination course at 2, 4 and 6 months of age.
Imunogenost cjepiva Infanrix hexa ocjenjivala se u 3 ispitivanja koja su uključivala približno 300 nedonoščadi (rođene nakon razdoblja gestacije od 24 do 36 tjedana) nakon ciklusa 3-doznog primarnog cijepljenja u dobi od 2, 4 i 6 mjeseci.
The immunogenicity of IXIARO administered in a rapid vaccination schedule was evaluated in a randomized, observer-blind, phase 3 study.
Imunogenost cjepiva IXIARO primijenjenog prema brzom rasporedu cijepljenja procijenjena je u randomiziranom ispitivanju faze 3, slijepom za promatrača.
The immunogenicity of IXIARO was evaluated in an open-label, uncontrolled trial in 200 healthy elderly persons aged 65 to 83 years, including subjects with stable underlying conditions like hypercholesterolemia, hypertension, cardiovascular disease or non insulin-dependent diabetes mellitus.
Imunogenost cjepiva IXIARO procijenjena je u otvorenom, nekontroliranom ispitivanju u 200 zdravih starijih odraslih osoba u dobi od 65 do 83 godine, uključujući ispitanike sa stabilnim osnovnim stanjima poput hiperkolesterolemije, hipertenzije, kardiovaskularne bolesti ili dijabetesa mellitusa neovisnog o inzulinu.
The immunogenicity of Kovaltry was evaluated in previously treated patients.
Imunogenost lijeka Kovaltry procijenjena je u prethodno liječenih bolesnika.
The immunogenicity of Nuwiq was evaluated in clinical trials in 135 previously treated patients with severe haemophilia A (74 adult and 61 paediatric patients).
Imunogenost lijeka Nuwiq je procijenjena u kliničkim ispitivanjima na 135 prethodno liječenih bolesnika s teškom hemofilijom A (74 odrasla i 61 pedijatrijski bolesnik).
The immunogenicity of one dose of Nimenrix has been evaluated in more than 8,000 subjects aged
Imunogenost jedne doze cjepiva Nimenrix ocijenjena je u više od 8000 ispitanika u dobi od
The immunogenicity of siltuximab has been evaluated using antigen-bridging enzyme immunoassay (EIA) and electrochemiluminescence (ECL)-based immunoassay (ECLIA) methods.
Imunogenost siltuksimaba bila je procijenjena koristeći enzimsko-imunološku pretragu (EIA) premoštavanjem antigenom i elektrokemiluminescentnom (ECL) imunometodom (ECLIA).
The immunogenicity of Synflorix following a 2-dose or 3-dose primary vaccination schedule in subjects less than 6 months of age was evaluated in a clinical study.
U kliničkom ispitivanju ocjenjivana je imunogenost cjepiva Synflorix u rasporedu primarnog cijepljenja s 2 doze ili 3 doze u ispitanika mlađih od 6 mjeseci.
The immunogenicity of the A/Vietnam/1203/2004 strain vaccine has been evaluated in a clinical trial in children and adolescents aged 9 to 17 years (N=288), in children aged 3 to 8 years (N=146) and in infants and children aged 6 to 35 months (N=33) following a 0, 21 day schedule.
Imunogenost cjepiva protiv soja A/Vietnam/1203/2004 procijenjena je u kliničkom ispitivanju u djece i adolescenata u dobi od 9 do 17 godina (N=288), u djece u dobi od 3 do 8 godina (N=146) i u dojenčadi i djece u dobi od 6 do 35 mjeseci (N=33) nakon režima primjene 0. i 21. dana.
The immunogenicity of the A/Vietnam/1203/2004 strain vaccine has been evaluated in three clinical studies in adults aged 18 – 59 years (N=961) and in two clinical studies in subjects aged 60 years and older (N=391) following a 0, 21 day schedule.
Imunogenost cjepiva soja A/Vietnam/1203/2004 procijenjena je u tri klinička ispitivanja u odraslih u dobi od 18 do 59 godina (N=961) te u dva klinička ispitivanja u ispitanika u dobi od 60 i više godina (N=391), nakon primjene 0. i 21. dana.
The immunogenicity of the vaccine containing 7.5 µg non-adjuvanted HA derived from strain A/Vietnam/1203/2004 has been evaluated in two clinical studies in adults aged 18 – 59 years (N = 312) and in older subjects aged 60 years and older (N = 272) following a 0, 21 day schedule.
Imunogenost cjepiva koje sadrži 7,5 µg neadjuvantiranog HA dobivenog iz soja A/Vietnam/1203/2004 procijenjeno je u dva klinička ispitivanja u odraslih u dobi od 18 do 59 godina (N = 312) te u starijih ispitanika u dobi od 60 godina naviše (N = 272) slijedeći raspored primjene 0. i 21. dana.
The immunogenicity of Vaxelis in children over 15 months of age has not been studied in clinical trials.
Imunogeničnost cjepiva Vaxelis u djece starije od 15 mjeseci nije ispitivana u kliničkim ispitivanjima.
The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.
Imunološki odgovor može biti oslabljen u bolesnika na imunosupresivnoj terapiji.
The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.
Imunološki odgovor može biti slabiji ako je bolesnik podvrgnut imunosupresivnom liječenju.
The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.
Kod bolesnika na imunosupresivnoj terapiji moguć je smanjen imunološki odgovor.
The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept serum concentrations.
.Utjecaj uznapredovale dobi ispitan je u populacijskoj analizi farmakokinetike serumskih koncentracija etanercepta.
The impact of Gardasil against the overall risk for cervical, HPV disease (i.e., disease caused by any HPV type) was evaluated starting 30 days after the first dose in 17,599 individuals enrolled in the two phase III efficacy trials (Protocols 013 and 015).
Utjecaj cjepiva Gardasil na ukupni rizik od bolesti vrata maternice uzrokovane HPV-om (tj. bolest uzrokovana bilo kojim tipom HPV-a) procijenjen je u 17 599 ispitanika uključenih u dva ispitivanja djelotvornosti faze III (Protokoli 013 i 015), počevši 30 dana nakon primitka prve doze cjepiva.
The impact of gender on the pharmacokinetics of Sivextro was evaluated in healthy males and females in clinical studies and in a population pharmacokinetics analysis.
Utjecaj spola na farmakokinetiku lijeka Sivextro procijenjen je u zdravih muškaraca i žena u kliničkim ispitivanjima i u populacijskoj farmakokinetičkoj analizi.
The impact of immunogenicity on asfotase alfa pharmacokinetic varied over time due to the time varying nature of immunogenicity and overall was estimated to decrease pharmacokinetic exposures by less than 20%.
Utjecaj imunogeničnosti na farmakokinetiku asfotaze alfa varirao je tijekom vremena zbog promjenjive prirode imunogeničnosti ovisno o vremenu, i u cjelini je procijenjeno da smanjuje farmakokinetičke izloženosti za manje od 20%.
The impact of long- term treatment with Humira on the development of autoimmune diseases is unknown.
Utjecaj dugotrajnog liječenja lijekom Humira na razvoj autoimunih bolesti nije poznat.
The impact of long-term treatment with Cimzia on the development of autoimmune diseases is unknown.
Nije poznat utjecaj dugotrajnog liječenja Cimzijom na razvoj autoimunih bolesti.